ArticlePloS one2009
Proteome serological determination of tumor-associated antigens in melanoma.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Serological Proteome Analysis for Antigen Identification.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Optimization of a high-throughput shotgun immunoproteomics pipeline for antigen identification.Journal of proteomics · 2023Article
- The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma.Advances in cancer research · 2023Review
- Immunoproteomic analysis of Clostridium botulinum type B secretome for identification of immunogenic proteins against botulism.Biotechnology letters · 2021Article
- Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review).International journal of oncology · 2020Review
- Chaperonin containing TCP1 subunit 5 is a tumor associated antigen of non-small cell lung cancer.Oncotarget · 2017Article
- Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Oncotarget · 2017Article
- Functional analysis of a novel glioma antigen, EFTUD1.Neuro-oncology · 2014Article
- Three are better than one: plasminogen receptors as cancer theranostic targets.Experimental hematology & oncology · 2013Article
- New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?Cancer gene therapy · 2013Review
- Galectin-3 and the skin.Journal of dermatological science · 2011Review
- CIG-DB: the database for human or mouse immunoglobulin and T cell receptor genes available for cancer studies.BMC bioinformatics · 2010Article
- Proteomic analysis of laser microdissected melanoma cells from skin organ cultures.Journal of proteome research · 2010Article
- Article
- Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteome serology may complement expression library-based approaches as strategy utilizing the patients' immune responses for the identification pathogenesis factors and potential targets for therapy and markers for diagnosis. Melanoma is a relatively immunogenic tumor and antigens recognized by melanoma-specific T cells have been extensively studied. The specificities of antibody responses to this malignancy have been analyzed to some extent by molecular genetic but not proteomics approaches. We screened sera of 94 melanoma patients for anti-melanoma reactivity and detected seropositivity in two-thirds of the patients with 2-6 antigens per case detected by 1D and an average of 2.3 per case by 2D Western blot analysis. For identification, antigen spots in Western blots were aligned with proteins in 2-DE and analyzed by mass spectrometry. 18 antigens were identified, 17 of which for the first time for melanoma. One of these antigens, galectin-3, has been related to various oncogenic processes including metastasis formation and invasiveness. Similarly, enolase has been found deregulated in different cancers. With at least 2 of 18 identified proteins implicated in oncogenic processes, the work confirms the potential of proteome-based antigen discovery to identify pathologically relevant proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.